This case study is an anonymised composite based on publicly reported commercial insurance claim patterns. It is not actual Apex client data and does not constitute legal or insurance advice. Names, locations and identifying details have been changed. Apex Insurance Brokers Limited is authorised and regulated by the Financial Conduct Authority, FRN 724952.
A specialist aesthetic medicine clinic based in a city centre in the South West, operating from a single first-floor consulting and treatment suite. Owned by a consultant dermatologist (the clinical lead) and operated as a limited company with two additional consultant practitioners (a plastic surgeon and a senior aesthetic nurse prescriber) working under associate arrangements. Annual turnover £1.4m. The clinic is registered with the Care Quality Commission as a regulated provider, and the clinical staff are registered with the General Medical Council and the Nursing and Midwifery Council respectively. Insurance includes medical malpractice (treatment risk) cover at £5m on a claims-made basis, public liability at £5m, employers’ liability at £10m, and the standard material damage and BI suite.
A 42-year-old patient underwent a series of injectable dermal filler treatments to the mid-face area carried out by the senior aesthetic nurse prescriber under the clinic’s standardised protocol. The patient had attended for an initial consultation with the clinical lead three weeks earlier and had signed a treatment consent form covering the proposed series of treatments, including general descriptions of the risks of bruising, swelling, infection and the rare but serious risks of vascular complications including skin necrosis and visual disturbance.
During the second treatment session, the patient experienced immediate severe pain in the cheek area and within minutes developed pallor of the skin over the cheek consistent with a vascular occlusion event. The treating nurse immediately ceased the procedure and initiated the clinic’s vascular occlusion emergency protocol, which included hyaluronidase injection to dissolve the filler material. Despite prompt intervention, the patient developed an area of partial skin necrosis over the cheek over the following days, and ultimately required surgical revision and laser treatment to manage the resulting scarring. The patient also developed transient visual disturbance during the immediate post-treatment period which fully resolved within seventy-two hours, but caused significant distress at the time.
The patient was referred urgently to a hospital plastic surgery service and was supported by the clinic throughout the recovery period. Subsequent investigations including specialist plastic surgical opinion concluded that the long-term aesthetic outcome included a permanently visible area of approximately two square centimetres of altered skin texture and pigmentation over the cheek.
The clinic’s incident reporting protocol was followed: the incident was notified internally within hours, the CQC was notified as a serious incident within forty-eight hours, the relevant professional regulators were notified as a personal-capacity matter by the treating nurse, and the insurer was notified by the broker on the day after the incident.
The patient instructed specialist medical negligence solicitors approximately eight months after the incident. Pleaded quantum was approximately £180,000: special damages including the cost of surgical revision and laser treatment (privately funded), additional cosmetic camouflage products and treatments, loss of earnings during the recovery period and reduced confidence affecting the patient’s professional role (the patient was a senior account manager in a client-facing role), and general damages for pain, suffering and loss of amenity based on the JC Guidelines tariff for facial scarring at approximately £45,000.
The pleading advanced three principal allegations: (a) negligent technique by the treating nurse in the placement of the filler material, leading to vascular occlusion; (b) inadequate informed consent in that the patient had not been adequately informed of the specific risk of vascular occlusion in mid-face filler treatment notwithstanding the general consent form references to vascular complications; and (c) inadequate emergency response in that the hyaluronidase intervention had not been initiated quickly enough to prevent the necrosis.
The legal framework for the consent allegation was developed under Montgomery v Lanarkshire Health Board [2015] UKSC 11 which established the test of informed consent based on what a reasonable patient in the position of the actual patient would want to know, rather than the historic Bolam-derived doctor-centred test. The Montgomery framework has been particularly impactful in the aesthetic medicine sector where the elective nature of treatment elevates the importance of informed consent.
The medical malpractice (treatment risk) policy was the operative cover. Notification was made within twenty-four hours of the incident, well inside policy notification requirements. The insurer engaged specialist medical negligence defence solicitors and instructed an independent expert plastic surgeon and an aesthetic medicine consultant as expert witnesses.
The defence position addressed each pleaded allegation. On technique, the experts concluded that vascular occlusion is a recognised complication of mid-face filler treatment occurring in approximately 1 in 6,000 treatments in published series, that the technique used was consistent with the protocols recommended by relevant aesthetic medicine professional bodies, and that the complication had occurred despite reasonable care. On emergency response, the experts concluded that the hyaluronidase intervention had been initiated within minutes of the recognition of the occlusion event, consistent with best practice timelines, and that the development of partial necrosis despite prompt intervention reflected the inherent risk of the underlying event rather than a failure of emergency response.
On the consent allegation, the defence was more difficult. The general consent form references to “vascular complications” were judged by the experts to fall short of the specificity required under the Montgomery test for a treatment with the elective profile of aesthetic dermal filler. The defence accepted that the consent process should have specifically identified vascular occlusion and skin necrosis as named risks rather than relying on general references.
The matter settled at mediation approximately eighteen months after the incident at £85,000 plus claimants’ costs of £42,000. The settlement reflected the technical defence’s relative strength on technique and emergency response, and the consent allegation’s relative weakness. Defence costs across the matter totalled approximately £38,000.
The clinic implemented a substantially revised consent process across all treatments, with specific named-risk consent forms developed for each treatment category, video-recorded consent discussions for higher-risk treatments, and a 48-hour cooling-off period between consent and treatment. The medical malpractice policy renewed with a 32% premium increase, an additional condition precedent on documented Montgomery-compliant consent for all elective treatments, and a £10,000 each-and-every-claim excess. The CQC registration was maintained subject to a routine inspection that examined the revised consent process and confirmed it as adequate.
The treating nurse was the subject of a Nursing and Midwifery Council referral that closed without further action approximately twelve months after the incident, accepting the technical adequacy of the treatment and the prompt emergency response.
The clinic’s wider practice was reviewed against the Joint Council for Cosmetic Practitioners and the British Association of Aesthetic Plastic Surgeons guidance, and several procedural refinements were implemented as best-practice upgrades.
Aesthetic medicine and similar elective healthcare exposures are one of the fastest-growing areas of medical malpractice claims in the UK and one where the legal framework has shifted significantly post-Montgomery. First, informed consent under the Montgomery v Lanarkshire Health Board [2015] framework requires specific identification of material risks that a reasonable patient in the position of the actual patient would want to know — generic consent forms are no longer adequate for elective treatments. Second, the medical malpractice policy should specifically cover all treatments provided by the clinic and all practitioners working under any arrangement; gaps for associate practitioners or specific treatment categories are surprisingly common. Third, the Care Quality Commission registration creates its own continuing obligations and the CQC engagement on serious incidents needs to be coordinated with the insurance and litigation response. Fourth, contemporaneous incident documentation — clinical records, witness accounts, photographs, timing of emergency response — is the central evidence base for any defence. Fifth, the professional regulator referral pathway (GMC, NMC, GPhC depending on practitioner) operates in parallel with the civil claim and requires separate engagement.
We would have reviewed the clinic’s consent process against the Montgomery framework at the previous renewal and would have specifically flagged the generic consent form wording as a known coverage and reputational exposure. The medical malpractice policy schedule would have been reviewed against the actual treatment portfolio and practitioner arrangements to ensure no gaps. At notification, we would have ensured that the CQC notification, the regulator referrals, the insurer notification and the patient liaison workstream were coordinated from day one, and would have engaged specialist medical defence counsel from the earliest stage on both the civil claim and the regulator workstreams.
For the underlying cover, see our Healthcare clinic insurance hub.
Apex Insurance Brokers serves UK professional services firms and commercial businesses. Call 0117 325 0027, email hello@apexinsurancebrokers.co.uk, or request a quotation.
Get a quote